Free Trial

Brainstorm Cell Therapeutics (BCLI) Insider Trading & Ownership

Brainstorm Cell Therapeutics logo
$1.86
-0.01 (-0.53%)
(As of 11/1/2024 ET)

Brainstorm Cell Therapeutics (NASDAQ:BCLI) Insider Buying and Selling Activity

Current
Insider Ownership
Percentage
6.70%
Number Of
Insiders Buying
(Last 12 Months)
1
Amount Of
Insider Buying
(Last 12 Months)
$5,057.70
Number Of
Insiders Selling
(Last 12 Months)
1
Amount Of
Insider Selling
(Last 12 Months)
$22,050.00
Get BCLI Insider Trade Alerts

Want to know when executives and insiders are buying or selling Brainstorm Cell Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily.

BCLI Insider Buying and Selling by Quarter

Brainstorm Cell Therapeutics Insider and Congressional Trades History

Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/30/2024Chaim LebovitsCEOBuy1,466$3.45$5,057.70  
7/19/2024Ibrahim B. DagherInsiderSell4,200$5.25$22,050.00  
(Data available from 1/1/2013 forward)

BCLI Insider Trading Activity - Frequently Asked Questions

The list of insiders at Brainstorm Cell Therapeutics includes Chaim Lebovits, Ibrahim B. Dagher, and Stacy Lindborg. Learn more on insiders at BCLI.

6.70% of Brainstorm Cell Therapeutics stock is owned by insiders. Learn more on BCLI's insider holdings.

The following insiders have purchased BCLI shares in the last 24 months: Chaim Lebovits ($5,057.70), and Stacy Lindborg ($20,337.30).

Insiders have purchased a total of 2,232 BCLI shares in the last 24 months for a total of $25,395.00 bought.

The following insider sold BCLI shares in the last 24 months: Ibrahim B. Dagher ($22,050.00).

Insiders have sold a total of 4,200 Brainstorm Cell Therapeutics shares in the last 24 months for a total of $22,050.00 sold.

Brainstorm Cell Therapeutics Key Executives

  • Mr. Chaim Lebovits (Age 53)
    President & Co-CEO
    Compensation: $878.78k
    1 recent trades
  • Dr. Irit Arbel DSc (Age 64)
    Ph.D., Co-Founder & Independent Vice Chair of the Board
  • Ms. Alla Patlis CPA (Age 37)
    M.B.A., Interim CFO & Controller
    Compensation: $130.92k
  • Mr. Uri Yablonka (Age 47)
    Executive VP, Chief Business Officer, Secretary & Director
    Compensation: $247.06k
  • Dr. Daniel Offen Ph.D.
    Chief Scientific Advisor
  • Ms. Mary Kay Turner
    Senior Vice President of Patient Advocacy & Government Affairs
  • Dr. Ibrahim Dagher M.D. (Age 55)
    Executive VP & Chief Medical Officer


This page (NASDAQ:BCLI) was last updated on 11/2/2024 by MarketBeat.com Staff
From Our Partners